Detalimogene Shows Enhanced Complete Response Rate of 62% After 6 Months
Trial Results: The LEGEND trial for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) has shown promising preliminary results, with a 63% complete response rate at any time and a favorable safety profile, including low rates of treatment-related adverse events (42%) and dose interruptions (1.6%).
Enrollment Success: The trial successfully exceeded its enrollment target, completing the pivotal cohort with 125 patients, and is set to support a Biologics License Application (BLA) submission planned for the second half of 2026.
Protocol Amendments: An amended protocol was implemented to align the trial with current guidelines, resulting in improved efficacy data, particularly a 62% complete response rate at 6 months for patients evaluated under the new protocol.
Future Plans: enGene anticipates providing further updates on the LEGEND trial and plans to engage with the FDA regarding a statistical analysis plan, with potential BLA filing and FDA approval expected in 2026 and 2027, respectively.
Trade with 70% Backtested Accuracy
Analyst Views on ENGN
About ENGN
About the author
enGene Holdings Inc. (ENGN) Expands $125M Debt Facility, Stock Rises 14%
- Stock Surge: enGene Holdings Inc. saw a 14% increase in stock price on Friday, closing at $12.12, which is a $1.48 gain from the previous session, reflecting strong market confidence in its financial health.
- Debt Facility Expansion: The company announced an expanded $125 million debt facility with Hercules Capital, Inc., which includes $100 million in new loan proceeds and $25 million to refinance existing debt, enhancing its financial flexibility.
- Strong Market Performance: ENGN's stock has risen in eight of the past nine trading sessions, climbing approximately 47% since January 6, and reached a new 52-week high of $12.25 on Friday, indicating investor optimism about its future potential.
- Clear Future Plans: CEO Ron Cooper stated that the additional capital will support the company's plans for a BLA filing in the second half of this year and a potential commercial launch in 2027, showcasing its strategic positioning in the gene therapy sector.
enGene Holdings Secures $125 Million Loan Agreement with Hercules Capital
- Financing Enhancement: enGene has entered into an amended loan agreement with Hercules Capital for up to $125 million in non-dilutive capital, strengthening the company's financial flexibility in preparation for its planned Biologics License Application (BLA) to the FDA in the second half of 2026.
- Clinical Trial Support: The loan agreement includes an initial $25 million for refinancing existing debt, with an additional $75 million available based on clinical and regulatory milestones, ensuring continued R&D in high-risk non-muscle invasive bladder cancer (NMIBC) treatment.
- Significant Market Potential: Approximately 75-80% of new bladder cancer diagnoses are NMIBC, with BCG-unresponsive patients facing a 50-70% recurrence rate, making enGene's detalimogene voraplasmid a promising innovative bladder-sparing treatment option to meet urgent market needs.
- Deepening Strategic Partnership: Hercules Capital's support underscores its commitment as a long-term capital partner and highlights the importance of financing innovative life sciences companies, aiding enGene in the potential commercial launch of detalimogene in 2027.
enGene Selected for FDA CDRP Program to Accelerate Drug Development
- FDA Program Participation: enGene's detalimogene voraplasmid has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, which aims to expedite clinical development timelines and provide patients with earlier access to therapies.
- Manufacturing Capacity Enhancement: Detalimogene has already been scaled to commercial manufacturing levels, and participation in the CDRP is expected to facilitate additional FDA interactions to ensure CMC readiness for a Biologics License Application (BLA) submission in the second half of 2026.
- Clinical Trial Progress: In the pivotal cohort of the LEGEND trial, detalimogene demonstrated a 62% six-month complete response rate among 125 high-risk NMIBC patients, indicating its potential effectiveness for BCG-unresponsive patients.
- Strategic Implications: This FDA recognition not only bolsters enGene's confidence in detalimogene's potential but also underscores the company's commitment to strong manufacturing practices, aiming to address the urgent medical needs of high-risk NMIBC patients.
Oppenheimer Affirms Outperform Rating for enGene Holdings and Increases Price Target to $33
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
Reasons Behind the Surge in enGene Holdings Stock Today
Stock Surge: enGene Holdings (ENGN) stock rose over 65% after promising preliminary results from its Phase 2 LEGEND trial for bladder cancer gene therapy, detalimogene voraplasmid.
Trial Results: The trial showed a 62% complete response rate at six months for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with a favorable safety profile.
FDA Approval Plans: enGene plans to submit its therapy for FDA approval in the second half of 2026, potentially enhancing its position in bladder cancer treatment.
Analyst Upgrades: Raymond James analyst Sean McCutcheon upgraded ENGN to a Buy rating with a price target of $27, citing strong trial enrollment and execution, and a Strong Buy consensus rating on Wall Street.
Dow Rises Over 300 Points; Energy Vault Holdings Stock Soars
Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.64% while the NASDAQ and S&P 500 fell by 0.79% and 0.23%, respectively.
Sector Highlights: Energy shares rose by 1.2%, while information technology stocks experienced a decline of 0.9%.
Notable Stock Movements: RealReal Inc. saw a significant rise after positive earnings, while enGene Holdings Inc. surged 72% following promising study results. Conversely, Vor Biopharma Inc. and Salarius Pharmaceuticals Inc. both dropped 50% due to public offering announcements.
International Markets: European shares increased, with the eurozone's STOXX 600 up 1.05%, while Asian markets closed mixed, with Japan's Nikkei 225 slightly down and India's BSE Sensex up 0.40%.
enGene Holdings Inc. (ENGN) Expands $125M Debt Facility, Stock Rises 14%
- Stock Surge: enGene Holdings Inc. saw a 14% increase in stock price on Friday, closing at $12.12, which is a $1.48 gain from the previous session, reflecting strong market confidence in its financial health.
- Debt Facility Expansion: The company announced an expanded $125 million debt facility with Hercules Capital, Inc., which includes $100 million in new loan proceeds and $25 million to refinance existing debt, enhancing its financial flexibility.
- Strong Market Performance: ENGN's stock has risen in eight of the past nine trading sessions, climbing approximately 47% since January 6, and reached a new 52-week high of $12.25 on Friday, indicating investor optimism about its future potential.
- Clear Future Plans: CEO Ron Cooper stated that the additional capital will support the company's plans for a BLA filing in the second half of this year and a potential commercial launch in 2027, showcasing its strategic positioning in the gene therapy sector.
enGene Holdings Secures $125 Million Loan Agreement with Hercules Capital
- Financing Enhancement: enGene has entered into an amended loan agreement with Hercules Capital for up to $125 million in non-dilutive capital, strengthening the company's financial flexibility in preparation for its planned Biologics License Application (BLA) to the FDA in the second half of 2026.
- Clinical Trial Support: The loan agreement includes an initial $25 million for refinancing existing debt, with an additional $75 million available based on clinical and regulatory milestones, ensuring continued R&D in high-risk non-muscle invasive bladder cancer (NMIBC) treatment.
- Significant Market Potential: Approximately 75-80% of new bladder cancer diagnoses are NMIBC, with BCG-unresponsive patients facing a 50-70% recurrence rate, making enGene's detalimogene voraplasmid a promising innovative bladder-sparing treatment option to meet urgent market needs.
- Deepening Strategic Partnership: Hercules Capital's support underscores its commitment as a long-term capital partner and highlights the importance of financing innovative life sciences companies, aiding enGene in the potential commercial launch of detalimogene in 2027.
enGene Selected for FDA CDRP Program to Accelerate Drug Development
- FDA Program Participation: enGene's detalimogene voraplasmid has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, which aims to expedite clinical development timelines and provide patients with earlier access to therapies.
- Manufacturing Capacity Enhancement: Detalimogene has already been scaled to commercial manufacturing levels, and participation in the CDRP is expected to facilitate additional FDA interactions to ensure CMC readiness for a Biologics License Application (BLA) submission in the second half of 2026.
- Clinical Trial Progress: In the pivotal cohort of the LEGEND trial, detalimogene demonstrated a 62% six-month complete response rate among 125 high-risk NMIBC patients, indicating its potential effectiveness for BCG-unresponsive patients.
- Strategic Implications: This FDA recognition not only bolsters enGene's confidence in detalimogene's potential but also underscores the company's commitment to strong manufacturing practices, aiming to address the urgent medical needs of high-risk NMIBC patients.
Oppenheimer Affirms Outperform Rating for enGene Holdings and Increases Price Target to $33
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
Reasons Behind the Surge in enGene Holdings Stock Today
Stock Surge: enGene Holdings (ENGN) stock rose over 65% after promising preliminary results from its Phase 2 LEGEND trial for bladder cancer gene therapy, detalimogene voraplasmid.
Trial Results: The trial showed a 62% complete response rate at six months for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with a favorable safety profile.
FDA Approval Plans: enGene plans to submit its therapy for FDA approval in the second half of 2026, potentially enhancing its position in bladder cancer treatment.
Analyst Upgrades: Raymond James analyst Sean McCutcheon upgraded ENGN to a Buy rating with a price target of $27, citing strong trial enrollment and execution, and a Strong Buy consensus rating on Wall Street.
Dow Rises Over 300 Points; Energy Vault Holdings Stock Soars
Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.64% while the NASDAQ and S&P 500 fell by 0.79% and 0.23%, respectively.
Sector Highlights: Energy shares rose by 1.2%, while information technology stocks experienced a decline of 0.9%.
Notable Stock Movements: RealReal Inc. saw a significant rise after positive earnings, while enGene Holdings Inc. surged 72% following promising study results. Conversely, Vor Biopharma Inc. and Salarius Pharmaceuticals Inc. both dropped 50% due to public offering announcements.
International Markets: European shares increased, with the eurozone's STOXX 600 up 1.05%, while Asian markets closed mixed, with Japan's Nikkei 225 slightly down and India's BSE Sensex up 0.40%.
